Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO: Apixaban for COVID-19 Thromboprophylaxis
NCT04746339Phase 4Terminated
- Sponsor
- Brazilian Clinical Research Institute
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apixaban in coronavirus disease 2019 (COVID-19), sponsored by Brazilian Clinical Research Institute. Started Mar 2021; status: terminated.
02
Drugs
apixaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04746339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746339.